Silence Therapeutics plc, a clinical-stage biotechnology company, has priced an underwritten public offering of 12,962,963 American Depositary Shares (ADSs) at $13.50 per ADS, according to a press release statement from the company.

The offering is expected to generate gross proceeds of approximately $175 million before deducting underwriting discounts, commissions, and other expenses. Silence Therapeutics has also granted underwriters a 30-day option to purchase up to an additional 1,944,444 ADSs at the public offering price, less underwriting discounts and commissions.

Each ADS represents three ordinary shares of £0.05 each in the capital of the company. The offering is expected to close on or about August 13, 2026, subject to customary closing conditions.

Jefferies, Morgan Stanley, Cantor, and William Blair are serving as joint book-running managers for the offering.

A shelf registration statement related to the offering was filed with the U.S. Securities and Exchange Commission on May 18, 2026, and declared effective on May 27, 2026.